When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants. Paris, October 9, 2024. Sanofi advances its ambition to protect all ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs . Late-breaking data show infant respiratory syncytial virus (RSV) ...

The highlight was nearly SEK 1.5 billion in royalties on RSV prophylactic Beyfortus from partner Sanofi, which helped drive Sobi's total revenue growth of 39% at constant exchange rates (16% ...

76% of patients in the Dupixent trial reached ≥75% improvement in eczema severity at 24 weeks. Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI ...